Personalized neoantigen vaccines based on the prediction of MHC class I epitopes can broaden and expand pre-existent tumor-specific cytotoxic CD8+ T cell responses, either as a stand-alone treatment or in conjunction with ICB therapy.9 Here, CD8A is linked to neoplasm.